TL;DR: Brands that come to us with a clear brief get samples in 2–3 weeks
TL;DR: “Reduces fine lines in 4 weeks” tells us which actives need to be present and at what load
Key Technical Parameters #
Getting encapsulation technology into a finished product starts long before we run the first lab batch. The real challenge isn’t the chemistry — it’s the handoff between what a brand owner has in their head and what we can actually build, test, and scale. Brands that come to us with a clear brief get samples in 2–3 weeks. Brands that don’t know what they want yet can spend 6–8 weeks just aligning on the concept before a single gram of material is weighed out. This guide walks through that process from our side of the bench — what we need from you, where briefs typically break down, and how to move from “I have an idea” to an approved formula ready for production.
What a Useful Formulation Brief Actually Contains #
When a brand partner sends us a brief that says “a serum with encapsulated retinol, clean, luxury feel” — that’s a starting point, not a brief. We need five things before we can begin.
The target claim. Not the marketing language. The functional outcome. “Reduces fine lines in 4 weeks” tells us which actives need to be present and at what load. “Overnight repair” tells us we need a controlled-release profile. “Visible pores minimised by morning” suggests a fast-release mechanism and probably a niacinamide or BHA co-active. The claim determines the encapsulation architecture — polymer microsphere, liposome, or cyclodextrin — and we cannot select that system without knowing what the product is supposed to do.
Texture and format. This matters more than most brand founders expect. A water-in-oil emulsion behaves completely differently from a lightweight essence when you try to disperse 200nm liposome particles through it. We ask for 3–5 benchmark products the brand likes the feel of. Not competitors — just textures. We use those as sensory anchors during evaluation. Without them, “silky but not oily” means something different to every person in the room.
Ingredient inclusions and exclusions. Clean beauty brands often come with a restricted list: no PEGs, no silicones, no synthetic fragrance. That’s fine — we work within these constraints regularly. What causes delays is when the exclusion list arrives after we’ve already selected our encapsulation matrix. PLGA polymer microspheres, for instance, use an organic solvent in the manufacturing process. Some brands flag this as incompatible with their “natural” positioning even though no solvent remains in the final product. We’d rather have that conversation on day one than at stability review.
Target markets. EU Cosmetics Regulation 1223/2009 restricts several encapsulation-related materials differently from US or China registration. Nanoparticle declarations, for example, are mandatory in the EU ingredient list. If a brand is entering Europe and the US simultaneously, the formula qualification pathway forks — and that affects timeline. We flag this in what we internally call the MRF-01 (Market Registration Flag) step during brief intake.
Budget signal. Not a hard quote request — just a direction. Encapsulated actives at 1–3% load can push cost-of-goods meaningfully compared to unencapsulated equivalents. We’ve had briefs that technically required a liposomal delivery system at 2% retinol, only to hit a retail price ceiling that made the unit economics impossible. Better to know that upfront.
| Brief Element | Why We Need It | What Happens Without It |
|---|---|---|
| Target claim | Determines encapsulation mechanism and active release profile | We default to our standard system, which may not match your efficacy story |
| Texture benchmarks | Calibrates sensory evaluation criteria for lab samples | Iteration cycles increase from ~2 to 4–5 rounds on average |
| Ingredient exclusions | Flags matrix incompatibilities before we begin | Reformulation after week 3 of stability adds 4–6 weeks to the project |
| Target market | Triggers correct regulatory pathway (EU nano declaration, NMPA filing) | You receive a formula that cannot be registered in your primary market |
| Budget signal | Eliminates systems that price out at retail | Development time spent on a formula that fails commercial viability review |
Where the Process Breaks Down — and the Conditions That Cause It #
This is the section worth reading carefully. Every failure mode below is something we encounter on a recurring basis, and most of them are preventable with better brief quality.
The benchmark mismatch. A brand founder sends a benchmark product — let’s say a popular encapsulated retinol serum from a mid-market US brand. They want something “similar but better.” When we run the benchmark through our internal sensory panel, it scores 4.1/5 on spreadability and 3.6/5 on skin feel at 1 hour. The brand wants both scores above 4.5. That’s a reasonable target. The problem appears when we start building toward it: the benchmark’s texture is partly a function of its silicone content, which the brand has excluded. You can’t have both. We almost always push back on this type of brief — not to be difficult, but because chasing a texture you’ve excluded the key ingredient for is a path to 8–10 formulation rounds with no resolution.
Stability failure from an undisclosed fragrance. Three out of five briefs that include fragrance don’t disclose the load level upfront. We’ve seen emulsion instability — visible phase separation within 6 weeks at 40°C — when fragrance load exceeded 0.9% in a liposome-containing formula. The fragrance’s alcohol carrier disrupts the phospholipid bilayer. At 0.5% or below, the same formula was stable through 12 weeks in our accelerated protocol. The brand didn’t mention fragrance at all in the initial brief; it came up in the second iteration. That cost six weeks.
The concentration-claim mismatch. A significant number of brands request “retinol 1%” on pack. At that concentration, using our encapsulation technology platform, the active load in the encapsulated particle needs to account for entrapment efficiency — typically 70–85% for our polymer microsphere system. So to deliver 1% free retinol equivalent, we’re dosing closer to 1.2–1.4% encapsulated material. Calling it “retinol 1%” on the label requires a clear internal definition of what’s being measured. This triggers a conversation about claim substantiation that some brands haven’t had with their regulatory consultant yet. We flag it. We don’t resolve it for them — that’s outside our scope — but we flag it every time.
Scale-up surprises. Lab batches run at 2–5kg. Pilot batches run at 50kg. Production runs at 300–500kg. The shear profile in a planetary mixer at 5kg is nothing like a high-shear homogeniser at 500kg, and liposome particle size distribution shifts under different processing conditions. We’ve seen mean particle diameter increase from 180nm at lab scale to 260nm at pilot scale — not catastrophic, but enough to change the release profile and potentially affect efficacy claims made from lab-scale data. Our QP-12 scale-up protocol includes a mandatory particle size recheck at pilot batch, specifically because of this. Brands that want to use lab-scale efficacy data for commercial claims should know this is a risk point.
The clinical data assumption. Brands sometimes ask us to reference efficacy data from the encapsulated ingredient supplier — say, a supplier-provided study showing a 32% improvement in skin hydration over 8 weeks using their liposomal hyaluronic acid. That data was generated on a specific formula at a specific concentration in a specific vehicle. When we build a different formula around the same ingredient, we cannot guarantee the same outcome. We’re not comfortable co-signing supplier-generated data as proof of performance for a brand’s label claims. If the brand needs clinical support for their own formula, they need an independent study. A split-face RCT (n=44, 8 weeks) evaluating a 1.5% encapsulated hyaluronic acid serum versus unencapsulated equivalent showed 27% greater improvement in transepidermal water loss reduction — but that was run on our specific formulation, with a defined particle size of 120–150nm and a specific release rate. Replicating that outcome requires replicating those parameters.
How Long Does This Actually Take? #
Faster than most brands expect, once the brief is solid.
Lab samples in 2–3 weeks from brief sign-off. Accelerated stability — 40°C/75% RH per ICH Stability Guidelines — runs 4–8 weeks concurrently with brand review. Real-time 24-month stability initiates at the same time. If you’re targeting EU Cosmetics Regulation 1223/2009 registration or NMPA Cosmetic Regulation filing, add 60–120 days for documentation review depending on the market.
Where brands lose time is in internal alignment — not in our lab. The approval chain between the founder, their retail buyer, their regulatory consultant, and their creative team can easily add 3–4 weeks after samples are delivered. We hold formula reservations for 90 days. After that, we require a new stability assessment before production.
Our anti-aging and encapsulation-forward formulas tend to follow a consistent rhythm: brief sign-off → lab sample delivery (2–3 weeks) → brand feedback → revision round if needed (1–2 weeks) → stability approval (4–8 weeks accelerated) → pilot batch (2 weeks) → production. The full cycle from a clean brief to first production batch is typically 14–20 weeks.
One thing worth saying directly: brands that try to compress the stability phase create problems at registration. Regulatory submissions require stability data. FDA Cosmetics Guidelines don’t mandate a specific stability duration for most cosmetics, but claim substantiation and safety assessments implicitly do. Skipping or truncating accelerated stability to hit a launch date is a risk the brand carries, not us.
Formulation Notes for Brand Partners #
When you brief us on an encapsulation project, the first questions we ask are about market and format. Those two variables change almost everything downstream — which encapsulation matrix we select, which preservative system we can use, which claim language will survive regulatory review.
The brief mistake we see most often: brands describe the product they want to launch instead of the problem they want to solve. “A luxury retinol serum with visible results in 4 weeks” is a launch brief. What we need is closer to “reduce consumer skin irritation while maintaining retinol efficacy, targeting first-time retinol users aged 28–45, primary market UK and Australia.” That second version tells us to use a slow-release polymer microsphere at 0.3–0.5% retinol equivalent, not a liposomal system at 1%. It’s a different formula entirely. Getting to it from the first brief takes two or three rounds of questions that could have been one clear intake document.
On timeline: lab samples in 2–3 weeks from signed brief, accelerated stability running 4–8 weeks, 24-month real-time stability initiated concurrently. Pilot batch slots are scheduled on a rolling 4-week queue. If you’re planning a launch, work backwards from your retail date and share it with us at brief stage — we’ll tell you immediately if the timeline is viable.
Development costs vary by project scope. Most encapsulation projects carry a formulation development fee, offset against first production order. MOQ for production typically starts at 500 units per SKU for encapsulated formats, with sample quantities of 50–100 units for evaluation.
Frequently Asked Questions #
We want to benchmark against a competitor product — can you reverse-engineer it?
We don’t do reverse engineering in the literal sense, but we do run competitive benchmarks through our sensory panel and use them as texture and performance anchors during development. What we actually build is original. If your benchmark uses ingredients on your exclusion list, we’ll tell you upfront that matching it exactly isn’t possible.
Do we need to submit a full regulatory dossier before you can start?
No — we start formulating from the brief, and the regulatory pathway runs in parallel. That said, if you’re targeting the EU and your formula will use nano-encapsulated materials, the EU Cosmetics Regulation 1223/2009 nano notification requirement affects how we write the INCI list and what supporting documentation we prepare. It depends on what market you’re entering, so tell us that at brief stage.
What’s the MOQ for samples before we commit to production?
For evaluation samples, we typically produce 50–100 units. Production MOQ for encapsulation-based formulas starts at 500 units per SKU, though this shifts depending on format complexity. The reason encapsulation projects carry a slightly higher MOQ than standard formulas is the encapsulation step itself — particle batch sizes have a minimum viable volume that affects per-unit cost below a certain threshold.
Three different OEMs gave us three different stability timelines — whose is right?
Accelerated stability at 40°C/75% RH for 4–8 weeks is the standard method per ICH Stability Guidelines, and it correlates reasonably well with 12–18 month real-time performance for most formats. The variation you’re seeing probably reflects different definitions of “pass” — some labs call a formula stable if it passes visual inspection, others require particle size recheck, pH drift within ±0.3, and preservative efficacy retest. Ask each OEM what their stability pass criteria actually are. The criteria matter more than the timeline.
We’re planning to launch simultaneously in the EU and US — is that a problem?
It adds documentation work, but it’s manageable if we know upfront. The EU requires nano ingredient declaration in the INCI list if particle size is below 100nm. The US FDA has no equivalent specific requirement for most cosmetics, though safety substantiation still applies. Where it gets complicated is if you’re using an encapsulated active that appears on the EU Cosmetics Regulation 1223/2009 restricted list — retinol in leave-on products for body care is a live example of this — because then the US and EU versions of the formula may need to differ in concentration. We’ve run dual-market projects before, but they require a branched brief and two separate stability packages. Plan for it, don’t retrofit it.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
